The antioxidant effects of statins

被引:123
作者
Davignon, J
Jacob, RF
Mason, RP
机构
[1] Clin Res Inst Montreal, Hyperlipidemia & Atherosclerosis Res Grp, Montreal, PQ H2W 1R7, Canada
[2] Univ Montreal Hosp, Med Ctr, Montreal, PQ, Canada
[3] Harvard Univ, Sch Med, Brigham & Womens Hosp, Cambridge, MA 02138 USA
[4] Elucida Res LLC, Beverly, MA USA
关键词
D O I
10.1097/01.mca.0000131573.31966.34
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Oxidative stress contributes to the initiation and the development of atherosclerotic plaques and adversely influences myocardial integrity. Statins interfere with oxidation in several ways that may contribute to reducing the atherogenic process. In addition to direct antioxidant effects, statins reduce circulating oxidized low-density lipoproteins (oxLDL) and inhibit their uptake by macrophages. They also reduce circulating markers of oxidation such as F2-isoprostane and nitrotyrosine. Statins inhibit oxidant enzymes activity such as that of reduced nicotinamide adenine dinucleotide phosphate (NAD[P]H) oxidase and myeloperoxidase and up-regulate the activity of antioxidant enzymes such as catalase and paraoxonase. They reduce endothelial dysfunction mainly by their ability to enhance enclothelial nitric oxide bioavailability, which is achieved by several mechanisms. The antioxidant properties of statins extend to organ protection especially the myocardium and the lungs. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:251 / 258
页数:8
相关论文
共 91 条
[1]   Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction [J].
Al Suwaidi, J ;
Hamasaki, S ;
Higano, ST ;
Nishimura, RA ;
Holmes, DR ;
Lerman, A .
CIRCULATION, 2000, 101 (09) :948-954
[2]   Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans [J].
Anderson, TJ ;
Meredith, IT ;
Charbonneau, F ;
Yeung, AC ;
Frei, B ;
Selwyn, AP ;
Ganz, P .
CIRCULATION, 1996, 93 (09) :1647-1650
[3]   Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dl treated with statins versus no lipid-lowering drug [J].
Aronow, WS ;
Ahn, C .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (02) :147-+
[4]   Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants [J].
Aviram, M ;
Rosenblat, M ;
Billecke, S ;
Erogul, J ;
Sorenson, R ;
Bisgaier, CL ;
Newton, RS ;
La Du, B .
FREE RADICAL BIOLOGY AND MEDICINE, 1999, 26 (7-8) :892-904
[5]   Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS .
ATHEROSCLEROSIS, 1998, 138 (02) :271-280
[6]   Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy [J].
Aviram, M ;
Hussein, O ;
Rosenblat, M ;
Schlezinger, S ;
Hayek, T ;
Keidar, S .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 31 (01) :39-45
[7]  
Benzie IFF, 1999, CLIN CHEM, V45, P901
[8]   Atorvastatin treatment-related changes to in vivo oxidant:: Antioxidant balance as assessed by plasma allantoin and lipid standardised vitamin E levels [J].
Benzie, IFF ;
Tomlinson, B ;
Chung, WY ;
Szeto, YT .
ATHEROSCLEROSIS, 1999, 144 :25-26
[9]   Prognostic value of myeloperoxidase in patients with chest pain [J].
Brennan, M ;
Penn, MS ;
Van Lente, F ;
Nambi, V ;
Shishehbor, MH ;
Aviles, RJ ;
Goormastic, M ;
Pepoy, ML ;
McErlean, ES ;
Topol, EJ ;
Nissen, SE ;
Hazen, SL .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (17) :1595-1604
[10]   Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins [J].
Brouet, A ;
Sonveaux, P ;
Dessy, C ;
Moniotte, S ;
Balligand, JL ;
Feron, O .
CIRCULATION RESEARCH, 2001, 89 (10) :866-873